Financial statements are reported in AUD. Prices converted from USD at today's exchange rate. Tranches and alerts stay in USD.
IMRN — Immuron Limited
A$ 1.29
A$ -0.05 (-3.52%)
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Market Cap
A$ 10.43M
Forward P/E
-87.5x
52-Week Range
N/A
IMRN Price History
Revenue vs. Net Income
A$ 7.7M
Revenue · FY2026
Annual. Net margin is shown under each year.
Free Cash Flow
-A$ 3.3M
FCF · FY2026
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-32.2%
ROCE · FY2026
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
6.6x
Assets ÷ liabilities · FY2026
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.1%
CapEx · FY2026
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+28.6%
Dilution · FY2026
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
